In the United States alone, over 6 million people have been diagnosed with Alzheimer’s disease, with the economic toll soaring to a staggering $321 billion annually; placing immense strain on caregivers and healthcare systems alike. OurMemos platform emerges as an innovator in this landscape, offering a groundbreaking approach to monitoring and assessing cognitive health in patients with Alzheimer’s and other dementias. With a vision to provide the best possible support for patients, the co-founders Fayez Azeez and Artem Iaryguine, aim to harness the power of real-time data and caregiver observations to enhance treatment strategies.
Alzheimer’s disease not only affects millions of individuals but also places a significant burden on caregivers. With 11 million Americans valiantly shouldering the burden of unpaid care, dedicating over 16 billion hours to support their loved ones. Yet, despite their commitment, they grapple with caregiver fatigue exacerbated by limited tools and resources. Concurrently, physicians navigate treatment plans in the absence of real-time data, to maximize their care.
OurMemos acknowledges this pressing need for support and aims to alleviate the challenges faced by patients, caregivers, and physicians alike. They aim to provide a comprehensive monitoring and assessment platform designed to support the treatment of Alzheimer’s and other dementias. The platform will seamlessly aggregate data from caregivers, patients, and healthcare professionals, leading to proactive and improved patient care.
For patients, OurMemos offers a lifeline, boasting a user-friendly interface that engages them in meaningful activities while discreetly monitoring cognitive health. Features such as meditation, music, and task lists promote brain stimulation and independence, enhancing the overall quality of life. On the other hand, caregivers find solace in a treasure trove of tools and resources, from daily activity tracking to medication reminders and access to educational materials and support groups. Real-time cognitive health data tracking empowers caregivers to stay ahead of the curve, while the patient's participation in self-assessments fosters a deeper understanding of their condition.
With plans to file for FDA approval as a Software as a Medical Device (SaMD), the platform aims to integrate seamlessly with electronic health records (EHR), enabling physicians to monitor patients remotely and adjust treatment plans as needed. OurMemos is currently registered with the Centers for Medicare & Medicaid Services (CMS) for reimbursement, ensuring accessibility for patients and caregivers. Moreover, the platform prioritizes HIPAA compliance, safeguarding patient data and privacy.
Looking ahead, OurMemos envisions extending its platform to address a spectrum of cognitive conditions beyond Alzheimer’s, including autism, stroke, and Parkinson’s disease, in addition to supporting clinical trials. Now, in pursuit of seeking investments, the co-founders state, “The funding would go towards building the application, obtaining the FDA approval certification, and creating public awareness.”
Jose Rodriguez, Chief Business Officer at OurMemos, states “We look forward to speaking with potential investors and partners to join us on this journey to provide the best care for patients.”
Media Contact
Name: Fayez Azeez
Email: media@ourmemos.com
Published by: Pathos Communications Ltd